Antibe Therapeutics Inc(Pre-Merger) ATBPF

Analysts upgrade

[Layth1990]

https://thedeepdive.ca/antibe-therapeutics-canaccord-upgrades-price-target-to-16-50/?fbclid=IwAR00XTN2a1SVf5s4ilc8pKOimGbHThIQXXbfRJrNUgodxDrfej37UlAX1zU

[JimmyJ]

Does anyone understand the table at the end of that article? Is "% market penetration" market share, and if so, why would they predict market share to peak at 2031?  I first I thought it was accumulative but then the sales numbers at the bottom don't make sense.  Seems to me like a poorly made table they should explain better or don't include it at all.    

[Layth1990]

First this rough estimate and it is only for china region which is 10% of total market. Market penetration % is the percentage of OA patients that will be using atb 346.  peak market will take years to achieve, why ? Because it takes time for doctors to prescribe it and people to shift if other nsaids won't work. Also, people and doctors feel more confident when a medication has been

[JimmyJ]

I fully agree; however, the year after peak (2032) there is a significant decrease in penetration and sales.  Why does it fall off to 1% penetration with only $52 sales from $472.  I would imagine once they hit peak, they would sustain that $472 going forward. Maybe I'm just reading it wrong but it certainly seems like something is off regardless how rough the estimates are. 

[Layth1990]

I think the patent will expire in 15 years so  cheap generic option will be allowed on the market. 472 million is for only 10% of the market. If it is fully commercialized it would be 4.72B  for that year 

[crow27]

Who are the six analysts and what are their price targets? I don't put to much faith in these guys but it's better they average $16.00 between them instead of $3.00 between them, hahaha. Stock is only trading at .55 cents before the RS and that folks is a sceaming buy.

[MrMugsy]

I also think you shouldn't worry too much about what happens after 2032.  If all goes to plan, we hopefully find ourselves a more efficient and more effective carrier molecule (like what we're doing with IBD) and we further extend our lead out to 2042. We'll need to wait and see ... but ... Antibe could rewrite the sales projections and the company valuations based on future R